CreaVax RCC Inj. can induce a powerful active immunity in cancer patients by enhancing the body's natural tendency to defend itself against malignant tumors. It is completely free from side effects or toxicity since it is an autologous dendritic cell-based tumor vaccine. In the clinical study in RCC patients, 11% of RCC patients achieved partial response and 56% of RCC patients achieved stable disease based on RECIST criteria. Median overall survival was 28.9 months which is more than two times of that of IL-2. There were no dose limiting toxicity (DLT) and no NCI grade 3 or 4 toxicity. CreaVax RCC Inj. was approved from the Korea Food & Drug Administration as a new drug in October, 2007.
CTP was developed through modeling of the PTD (Protein Transduction Domain) in HIV-1 TAT protein. CTP can transport attached bio-polymers like nucleic acids or proteins into the cell with high permeation efficiency, 2 to 5 times better than PTD. Since NLS (nuclear localization signal) of the PTD has been modified so as not to transport substance into the nucleus, CTP can minimize gene damages caused by attached bio-polymers by keeping them in the cytoplasm not in the nucleus. CTP shows much less cytotoxicity than other cell penetration peptides such as PTD or poly-Arg. Especially, CTP shows the specific tropism to the liver and lymph node in mouse models.